Novavax | NVAX - Créances Commerciales





Créances Commerciales Changement Date
Adma Biologics USD 158.43M 20.76M 2025-12
Agenus USD 22.44M 1.14M 2025-12
AstraZeneca USD 17.88B 1.17B 2026-03
BioCryst Pharmaceuticals USD 106.82M 15.49M 2025-12
Cassava Sciences USD 120K 697K 2025-12
Geron USD 39.23M 1.57M 2025-12
GlaxoSmithKline GBP 7.94B 178M 2026-03
MannKind USD 28.14M 10.23M 2026-03
Merck USD 11.78B 345M 2025-12
Moderna USD 71M 113M 2026-03
Novartis USD 12.29B 3.3B 2025-12
Novavax USD 106.45M 72.27M 2025-12
Pfizer USD 16.17B 332M 2026-03
Sanofi EUR 482M 85M 2026-03
Sarepta Therapeutics USD 547.91M 149.68M 2026-03
TG Therapeutics USD 392.05M 86.42M 2026-03